July 23, 2010

Takeda Pharmaceutical Company Limited

Approval of an Additional Indication of
“Takepron^® Capsules 15” and “Takepron^® OD Tablets 15” in Japan
for Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer
during Low-dose Aspirin Administration

Osaka, Japan, July 23, 2010 -Takeda Pharmaceutical Company Limited (“Takeda”) today announced that an additional indication of “Takepron® Capsules 15” and “Takepron® OD Tablets 15” for prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration was approved on July 23 by the Ministry of Health, Labour and Welfare. Takepron is a proton pump inhibitor discovered by Takeda and has been launched since 1992 in Japan.

The number of patients taking low-dose aspirin for prevention of relapse of cerebral infarction or myocardial infarction is increasing with the aging of the population in Japan. Administration of low-dose aspirin for a long period sometimes causes gastric or duodenal ulcer, however, discontinuing of administration may make patients face a higher risk of forming blood clots and emboli. Therefore, it is considered that extended use of low-dose aspirin while preventing an onset of ulcers is important. In light of the circumstance that there have been no drugs which have an indication for prevention of ulcers during low-dose aspirin administration in Japan, Takeda submitted an application for an additional indication of “Takepron Capsules 15” and “Takepron OD Tablets 15” for prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration.

“With the approval of this additional indication, we expect that Takepron helps patients who have a history of ulcers and take low-dose aspirin to prevent recurrence of ulcers,” said Yasuhiko Yamanaka, a member of the Board, Senior Vice President, Pharmaceutical Marketing Division of Takeda. “We will continue to pursue every possibility of our products, including from a point of view of prevention of disease, to further enhance their values and contribute to the better health of patients.”

(Reference)

###